Clinical trials
Primary Hepatocellular Carcinoma clinical trials
Below are recruiting primary hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 185 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05482516RecruitingPhase 3
Testing blood test–guided treatment for GI cancers in remission
This Phase 3 study tests whether giving treatment based on a positive blood test for “minimal cancer signals” (ctDNA) can help people with certain GI cancers stay cancer-free longer. It focuses on people who have finished curative-intent therapy and currently have no visible disease on scans, but their blood test is still positive.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05502198Recruiting
How muscle loss matters in advanced liver disease
This study looks at how loss of muscle strength or mass (sarcopenia) relates to advanced liver disease. It may help doctors understand which patients are at higher risk and could guide future care choices.
EksjöAges 18 years+ - NCT05623150Recruiting
Biopsy-based study for alcohol and metabolic liver disease
This trial studies people with liver disease linked to alcohol use or metabolic syndrome (a cluster of conditions like weight gain and insulin resistance). It uses recent standard-of-care liver biopsy results to better understand these chronic liver problems and how they relate to cancer risk.
NiceAges 18 years+ - NCT05652920RecruitingPhase 1/Phase 2
CAR T-cell therapy for liver cancer that has GPC3
This early-phase study tests modified immune T cells (CAR T cells) to treat hepatocellular carcinoma (HCC), a type of liver cancer, when the tumor shows a marker called GPC3. It may help shrink tumors or slow cancer growth, especially after other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–70 - NCT05690048RecruitingPhase 2
Fecal transplant to help liver cancer respond to standard drugs
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT05718492Recruiting
Tested HAIC for liver cancer after prior immunotherapy
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
Guangzhou, GuangdongAges 18–75 - NCT05751343RecruitingPhase 2
Test atezolizumab and bevacizumab with liver cancer procedures
This Phase 2 trial tests whether atezolizumab plus bevacizumab, given along with liver cancer treatment procedures (TACE/HAIC), can help people with advanced liver cancer that cannot be removed by surgery. It mainly looks at whether these medicines can control the cancer more effectively and safely.
Guangzhou, GuangdongAges 18–75 - NCT05794048Recruiting
Study of blood and tumor features in liver and pancreatic cancers
This trial looks at a patient’s “metabolic profile” (how the body’s chemicals are used) in people with certain liver and pancreatic tumors. It may help doctors better understand these cancers and improve how they are evaluated for treatment.
ClichyAges 18 years+ - NCT05803928RecruitingPhase 1
Ablation plus lenvatinib and anti-PD-1 to prevent liver cancer return
This early-phase study tests whether adding medicines to ablation (heating/freezing to destroy liver tumors) can keep liver cancer from coming back. It’s for people whose liver cancer recurred after prior surgery/ablation but still fits specific criteria, with the goal of improving disease control.
Guangzhou, GuangdongAges 18–75 - NCT06031285RecruitingPhase 2
Perioperative immunotherapy plus TACE-HAIC for liver cancer with portal vein tumor thrombus
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
Guangzhou, GuangdongAges 18–75 - NCT06041477RecruitingPhase 3
Combining treatments for liver cancer before surgery
This study tests whether giving targeted therapy and immunotherapy at the same time or one after the other is better for shrinking liver tumors that can't be removed right now but might be removable after treatment.
Guangzhou, GuangdongAges 18–75 - NCT06349317RecruitingPhase 2
Radiation, immunotherapy, and targeted therapy before surgery for liver cancer with portal vein tumor thrombus
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
Fuzhou, FujianAges 18–75 - NCT06454578RecruitingPhase 2
Study of adebrelimab plus apatinib after liver cancer surgery
This trial is testing a combination of two drugs (adebrelimab and apatinib) after liver cancer surgery to see if it can lower the chance of the cancer returning. It is for people whose tumors had high-risk features.
Jinan, ShandongAges 18 years+ - NCT06508307RecruitingPhase 1
A study of an injected virus for advanced solid tumors
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
Zhengzhou, HenanAges 18–75 - NCT06544083Recruiting
Blood test for early liver cancer detection
This trial is testing if a blood test can find liver cancer early. It may help people who are newly diagnosed or suspected to have liver cancer and have not started treatment yet.
Hangzhou, ZhejiangAges 18–75 - NCT06577272Recruiting
Predicting cancer return after tumor ablation
This study looks at people with liver cancer who are treated with a procedure called radiofrequency ablation (RFA). It aims to create a tool that can predict the chance of the cancer coming back after treatment.
Hangzhou, ZhejiangAges Any age - NCT06609876Recruiting
Donafenib after ablation for recurrent liver cancer
This trial tests whether taking the drug donafenib after a procedure called ablation (which destroys liver tumors) can help keep your liver cancer from returning. It is for people whose liver cancer has come back within the past year and who have small, treatable tumors.
Beijing, None SelectedAges 18–75 - NCT06622031Recruiting
TIPS with lenvatinib and immunotherapy for advanced liver cancer
This trial combines a procedure called TIPS (which helps relieve pressure in the liver) with two drugs—lenvatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—for people with advanced liver cancer that has spread into the main vein of the liver. It aims to see if this combination can help control the cancer and improve symptoms.
Beijing, None SelectedAges 18–75 - NCT06689670Recruiting
Liver tumor ablation with a needle-based device
This trial tests a needle-based device that uses heat or cold to destroy liver tumors. It is for people with primary or secondary liver cancer who cannot have surgery or a transplant.
Topkapı, IstanbulAges 18–100 - NCT06726161RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced liver cancer
This trial tests a new way to find and treat liver cancer that cannot be removed by surgery. First, a special dye (RYZ811) is used to see if your cancer cells have a marker called GPC3. If they do, you may receive a targeted radiation treatment (RYZ801) that seeks out those cells. This trial is for people whose liver cancer has grown despite receiving at least one prior therapy.
Birmingham, AlabamaAges 18 years+ - NCT06841172RecruitingPhase 3
Radiation vs treatment switch for limited liver cancer growth
This trial tests whether giving radiation to a few growing cancer spots while continuing your current treatment works better than switching to a new treatment right away. It's for people whose advanced liver cancer has only barely started to progress on their first therapy.
Jinan, ShandongAges 18–75 - NCT06864195Recruiting
Breath test for liver cancer detection
This study tests a simple breath test to detect liver cancer and monitor liver health. It is looking for patients with liver cancer, liver cirrhosis, primary sclerosing cholangitis, or people with normal livers to see if the breath test can help tell the difference.
LondonAges 18 years+ - NCT06898398Recruiting
TACE before surgery for large liver cancer
This trial combines a procedure called TACE (which blocks the blood supply to the tumor) with surgery to remove a large liver tumor. It is for people newly diagnosed with a large liver cancer that hasn't spread and can be completely removed with surgery.
Beijing, Beijing MunicipalityAges 18–75 - NCT06905262Recruiting
Finding cancer targets for liver cancer immunotherapy
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
NaplesAges 18–100
Hear when a new Primary Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary hepatocellular carcinoma?
- Yes. Clin2 currently lists 185 recruiting primary hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.